Abstract
Objective: analysis of pathogenetic and symptomatic therapy of community-acquired pneumonia in the prehospital and at the stage of hospital treatment of disease in hospitals of city Khujand of the Republic of Tajikistan. Materials and methods: A retrospective analysis of 393 case histories of patients treated for community-acquired pneumonia in the hospital Khujand from 2011 to 2015 is conducted. The estimation of the scope and efficiency of the additional medical support for the treatment of communityacquired pneumonia was conducted, take into account the drugs that given to patients in an outpatient setting and in a hospital. Analyzed purpose rationale, adequacy of dose, duration of treatment and compliance of the activities with existing international and national guidelines for the treatment of community-acquired pneumonia. Results: the study found that in clinical practice, 57% of patients with community-acquired pneumonia received funds pathogenetic and symptomatic therapy. It is found that quite often prescribed drugs with unproven efficiency. Thus, 75% of patients received expectorants and mucolytic drugs, 42.2% of patients received anti-allergic medicals. Non-steroidal anti-inflammatory medicals received 37.9% of patients with community-acquired pneumonia, almost 30% of patients receiving infusion therapy. Quite often (15.7%) patients with community-acquired pneumonia prescribed antifungal drugs and antiprotozoal drug – metronidazole (59% of cases). Furthermore, in complex treatment of community-acquired pneumonia include vitamin C (23.1%) and vitamin B (65.9%). Conclusion: the analysis of pharmacotherapy community-acquired pneumonia showed that in the treatment of this disease occurs unjustified polypharmacy. Quite often prescribe drugs with unproven efficacy and, as a consequence of a significant frequency of clinical failures at both the outpatient and inpatient, which significantly increases the cost of treatment. From the standpoint of evidence-based medicine is justified by the inclusion in the treatment of communityacquired pneumonia, only a mucolytic drugs and indications NSAIDs as an antipyretic and analgesic short course. The use of most drugs of pathogenic therapy do not have the evidence base and the efficiency of their purpose can not be considered reasonable. In this case, the analysis can serve as a basis for planning a set of measures for improvement of pharmacotherapy community-acquired pneumonia based on the principle of minimal sufficiency.
Highlights
Objective: analysis of pathogenetic and symptomatic therapy of community-acquired pneumonia in the prehospital and at the stage of hospital treatment of disease in hospitals of city Khujand of the Republic of Tajikistan
По данным ВОЗ, более 10% всех госпитализаций с острой патологией вызваны пневмониями
В основном, назначения нестероидные противовоспалительные средства (НПВС) связаны с лихорадкой (21%), реже – с болями в грудной клетке (4%)
Summary
Резюме Цель: анализ патогенетической и симптоматической терапии внебольничной пневмонии на догоспитальном этапе и на этапе стационарного лечения заболевания в стационарах г. Результаты: в ходе исследования выявлено, что в клинической практике 57% больных внебольничной пневмонией получали средства патогенетической и симптоматической терапии. Установлено, что достаточно часто назначают лекарственные средства с недоказанной эффективностью. Нестероидные противовоспалительные средства получали 37,9% больных с внебольничной пневмонией, почти 30% больных получали инфузионную терапию. Достаточно часто (15,7%) больным с внебольничной пневмонией назначались антимикотические препараты и противопротозойный препарат – метронидазол (в 59% случаев). Заключение: проведенный анализ фармакотерапии внебольничной пневмонии показал, что в лечении данного заболевания имеет место неоправданная полипрагмазия. Достаточно часто назначают лекарственные средства с недоказанной эффективностью, и, как следствие значительна частота клинических неудач как на этапе амбулаторного лечения, так и в стационарных условиях, что значительно удорожает курс лечения. С позиций доказательной медицины, оправдано включение в лечение внебольничной пневмонии лишь муколитических препаратов и по показаниям нестероидных про-
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.